On December 27, 2024, with approval from the National Medical Products Administration, Zhuhai United Bio-Pharmaceutical Co., Ltd. and its three pipeline products, Liraglutide Injection, Insulin Degludec Injection, and Semaglutide Injection, were included in the first batch of segmented biopharmaceutical production enterprises and pilot products in Guangdong Province. This breakthrough demonstrates TUL』s strength in biopharmaceutical production and R&D, while laying a solid foundation for meeting market demand and enhancing production efficiency and product quality.